The company says is the world’s only provider of Focal Molography – a novel label-free biosensor platform for direct imaging of biomolecular interactions in living cells. Molography enables customer from the pharma industry to measure binding and dissociation rates of molecular interactions in a robust and sensitive way while offering unique information such as linking extracellular binding information to internal cell responses.
Innovation: Focal Molography – a novel label-free biosensor platform for direct imaging of biomolecular interactions in living cells.
Application: Drug discovery market
Focal molography is a nanotechnology-based method that combines photolithography, molecular self-assembly and state-of-the-art optical technology. The company says it is a truly interdisciplinary technology, inspired by physics, tailored for biology and implemented for biomolecular interaction analysis.
Central to the technology is a biological surface structure termed mologram, which is part of the company’s patented sensor chip. Bound biomolecules on the mologram function as “detectives” that selectively recognize the target sample analyse, binding to them and emitting a light signal.
This signal indicates the exact measure of binding affinity between recognition site and analyte. This coherent signal can be measured in the so-called molographic focus or spot of light in the instrument’s detector array. One diffraction-limited mologram spot, less than one micrometre in diameter, represents one binding signal. Multiple molograms can be assembled on a tiny chip, meaning that multiple parameters can be measured swiftly, with great selectivity and sensitivity.
The company’s initial focus is providing the technology to the drug discovery market.
Subscribe for alerts on new companies featured on Startups.Bio
- AllozymesAllozymes is applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and […]
- Blacksmith MedicinesBlacksmith Medicines is using its purpose-built platform for metalloenzyme-targeted medicines to rationally […]
- Ambagon TherapeuticsAmbagon Therapeutics aims to develop first in class protein-protein interaction stabilizer drugs […]
- i2O TherapeuticsFounded by a team of researchers from Harvard University, i2O Therapeutics is […]